股本结构
单位：万股
| 公告日期 | 2024-03-22 | 2024-03-22 | 2024-03-28 | 2023-12-15 | 2023-10-04 | 2023-10-04 |
|---|---|---|---|---|---|---|
| 证券总股本 | 251.92 | 237.17 | 237.00 | 236.53 | 5913.36 | 5907.35 |
| 普通股本 | 251.92 | 237.17 | 237.00 | 236.53 | 5913.36 | 5907.35 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-22 | 2024-03-19 | 2023-12-31 | 2023-12-19 | 2023-09-15 | 2023-08-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-22 | 251.92 | 未披露 |
更多>>
Common stock offered 147,500 shares by the company
|
2024-03-22 |
| 2024-03-22 | 237.17 | 未披露 | 定期报告 | 2024-03-19 |
| 2024-03-28 | 237.00 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Sales of common stock and in public offering, net of offering costs
Sales of common stock through the at-the-market offering
|
2023-12-31 |
| 2023-12-15 | 236.53 | 未披露 |
更多>>
TFF Pharmaceuticals, Inc. announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares.
|
2023-12-19 |
| 2023-10-04 | 5913.36 | 未披露 | 定期报告 | 2023-09-15 |
| 2023-10-04 | 5907.35 | 未披露 | 定期报告 | 2023-08-31 |
| 2023-08-16 | 5614.92 | 未披露 |
更多>>
Common stock offered 19,896,000 shares by the company
|
2023-08-17 |
| 2023-08-14 | 3625.32 | 未披露 | 定期报告 | 2023-08-11 |
| 2023-03-31 | 3619.31 | 未披露 |
更多>>
From December 31, 2021 to December 20, 2022
Sales of common stock through the at-the-market offering, net of offering costs
Issuance of common stock for stock option exercises
Sales of common stock and warrants through public offering, net of offering costs
|
2022-12-20 |
| 2022-11-18 | 3480.07 | 未披露 |
更多>>
Common stock offered 9,282,609 shares by the company
|
2022-11-22 |
| 2022-11-14 | 2551.81 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Sale of common stock, net of offering costs
Issuance of common stock for stock option exercises
|
2022-09-30 |
| 2022-09-21 | 2547.78 | 未披露 | 定期报告 | 2022-09-16 |
| 2022-08-11 | 2544.59 | 未披露 | 定期报告 | 2022-08-05 |
| 2022-05-11 | 2537.38 | 未披露 | 定期报告 | 2022-05-09 |
| 2021-08-12 | 2537.18 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock for stock option exercises
|
2021-06-30 |
| 2021-05-13 | 2536.43 | 未披露 |
更多>>
From January 1, 2021 to March 31, 2021
Sale of common stock, net of offering costs
Issuance of common stock for stock option exercises
Issuance of common stock for warrant exercises
|
2021-03-31 |
| 2021-03-30 | 2467.49 | 未披露 |
更多>>
1.Common stock offered by the company 2,140,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 22,534,874 shares of common stock outstanding as of December 31, 2020.
|
2021-03-30 |
| 2021-03-26 | 2322.43 | 未披露 | 定期报告 | 2021-03-25 |
| 2021-03-10 | 2313.99 | 未披露 | 定期报告 | 2021-03-05 |
| 2021-03-10 | 2253.49 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Sale of common stock, net of offering costs
Issuance of common stock for accrued research and development expense
Issuance of common stock for stock option exercises
Issuance of common stock in connection with cashless warrant exercises
|
2020-12-31 |
| 2020-11-05 | 2222.63 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Sale of common stock,net of offering costs
Issuance of common stock in connection with cashless warrant exercises
|
2020-09-30 |
| 2020-09-09 | 2228.62 | 未披露 | 定期报告 | 2020-09-09 |
| 2020-08-28 | 2176.35 | 未披露 | 定期报告 | 2020-08-18 |
| 2020-08-13 | 1867.17 | 未披露 | 定期报告 | 2020-06-30 |
| 2020-04-29 | 1867.17 | 未披露 | 定期报告 | 2020-04-22 |
| 2020-05-14 | 1867.17 | 未披露 |
更多>>
From January 1, 2020 to March 24, 2020
Issuance of common stock for accrued research and development expense
|
2020-03-24 |
| 2020-03-27 | 1845.10 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common stock in connection with IPO, including underwriter’s over- allotment, net of offering costs and underwriter’s discount
Conversion of Series A Preferred Stock (including accrued dividends) to common stock
|
2019-12-31 |
| 2019-12-09 | 1845.10 | 未披露 | 定期报告 | 2019-12-09 |
| 2019-10-25 | 1782.54 | 未披露 |
更多>>
1.Common stock offered by us 4,400,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 13,425,436 shares of common stock outstanding as of the date of this prospectus (including preferred stock on an as-converted basis as of June 30, 2019 assuming a conversion price of $2.50 per share of the Series A preferred stock)
|
2019-10-25 |
| 2019-12-09 | 400.00 | 893.00 | 定期报告 | 2019-09-30 |
| 2019-08-20 | 400.00 | 566.20 | 定期报告 | 2019-06-30 |
Common stock offered 147,500 shares by the company
From December 31, 2022 to December 31, 2023
Sales of common stock and in public offering, net of offering costs
Sales of common stock through the at-the-market offering
TFF Pharmaceuticals, Inc. announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares.
Common stock offered 19,896,000 shares by the company
From December 31, 2021 to December 20, 2022
Sales of common stock through the at-the-market offering, net of offering costs
Issuance of common stock for stock option exercises
Sales of common stock and warrants through public offering, net of offering costs
Common stock offered 9,282,609 shares by the company
From June 30, 2022 to September 30, 2022
Sale of common stock, net of offering costs
Issuance of common stock for stock option exercises
From March 31, 2021 to June 30, 2021
Issuance of common stock for stock option exercises
From January 1, 2021 to March 31, 2021
Sale of common stock, net of offering costs
Issuance of common stock for stock option exercises
Issuance of common stock for warrant exercises
1.Common stock offered by the company 2,140,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 22,534,874 shares of common stock outstanding as of December 31, 2020.
From December 31, 2019 to December 31, 2020
Sale of common stock, net of offering costs
Issuance of common stock for accrued research and development expense
Issuance of common stock for stock option exercises
Issuance of common stock in connection with cashless warrant exercises
From June 30, 2020 to September 30, 2020
Sale of common stock,net of offering costs
Issuance of common stock in connection with cashless warrant exercises
From January 1, 2020 to March 24, 2020
Issuance of common stock for accrued research and development expense
from December 31, 2018 to December 31, 2019
Issuance of common stock in connection with IPO, including underwriter’s over- allotment, net of offering costs and underwriter’s discount
Conversion of Series A Preferred Stock (including accrued dividends) to common stock
1.Common stock offered by us 4,400,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 13,425,436 shares of common stock outstanding as of the date of this prospectus (including preferred stock on an as-converted basis as of June 30, 2019 assuming a conversion price of $2.50 per share of the Series A preferred stock)